| Literature DB >> 35832515 |
Rakesh Kumar Bachheti1,2, Limenew Abate Worku1,2, Yilma Hunde Gonfa1,3, Meseret Zebeaman1,2, D P Pandey4, Archana Bachheti5.
Abstract
Cardiovascular diseases (CVDs) are the world's leading killers, accounting for 30% deaths. According to the WHO report, CVDs kill 17.9 million people per year, and there will be 22.2 million deaths from CVD in 2030. The death rates rise as people get older. Regarding gender, the death rate of women by CVD (51%) is higher than that of men (42%). To decrease and prevent CVD, most people rely on traditional medicine originating from the plant (phytochemicals) in addition to or in preference to commercially available drugs to recover from their illness. The CVD therapy efficacy of 92 plants, including 15 terrestrial plants, is examined. Some medicinal plants well known to treat CVD are, Daucus carota, Nerium oleander, Amaranthus Viridis, Ginkgo biloba, Terminalia arjuna, Picrorhiza kurroa, Salvia miltiorrhiza, Tinospora cordifolia, Mucuna pruriens, Hydrocotyle asiatica, Bombax ceiba, and Andrographis paniculate. The active phytochemicals found in these plants are flavonoids, polyphenols, plant sterol, plant sulphur compounds, and terpenoids. A general flavonoid mechanism of action is to prevent low-density lipoprotein oxidation, which promotes vasodilatation. Plant sterols prevent CVD by decreasing cholesterol absorption in the blood. Plant sulphur compound also prevent CVD by activation of nuclear factor-erythroid factor 2-related factor 2 (Nrf2) and inhibition of cholesterol synthesis. Quinone decreases the risk of CVD by increasing ATP production in mitochondria while terpenoids by decreasing atherosclerotic lesion in the aortic valve. Although several physiologically active compounds with recognized biological effects have been found in various plants because of the increased prevalence of CVD, appropriate CVD prevention and treatment measures are required. More research is needed to understand the mechanism and specific plants' phytochemicals responsible for treating CVD.Entities:
Year: 2022 PMID: 35832515 PMCID: PMC9273387 DOI: 10.1155/2022/5741198
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Figure 1Important plants used in the treatment and prevention of cardiovascular diseases: (a) Daucus carota, (b) Nerium oleander, (c) Amaranthus Viridis, (d) Ginkgo biloba, (e) Terminalia arjuna, (f) Picrorhiza kurroa, (g) Salvia miltiorrhiza, (h) Tinospora cordifolia, (i) Mucuna pruriens, (j) Hydrocotyle asiatica, (k) Bombax ceiba, and (l) Andrographis paniculata.
Figure 2The chemical structure of epicatechin (EC) (a), epigallocatechin (EGC) (b), epicatechin-3-gallate (ECG), and epigallocatechin-3-gallate (c).
Figure 3The chemical structure of bioactive compounds found in coffee. (a) Caffeine. (b) Cafestol. (c) Chlorogenic acid. (d) Kahweol.
Figure 4Structure of some flavonoids used to treat CVD. (a) Myricetin. (b) Naringenin. (c) Naringenin-7-O-glucoside. (d) Quercetin.
Figure 5Plant sterols used to treat CVD. (a) Stigmasterol. (b) Campesterol. (c) Beta-sitosterol.
Figure 6Some terpenoid structures used to treat cardiovascular disease. (a) Rubiarbonone C. (b) β-sitosterol glycoside. (c) Ursolic acid. (d) Asiatic acid. (e) Betulinic acid. (f) Boswellic acid.
Figure 7The schematic representation of sulforaphane and allicin CVD prevention mechanism.
Important phytochemicals reported for the treatment of cardiovascular diseases.
| The scientific name of the plant | Family | Parts of plant | Phytochemical compounds | Actions/uses | Reference |
|---|---|---|---|---|---|
|
| Amaranthaceae | Whole plant part | Amino acids | Treats hypercholesterolemia | [ |
|
| Lauraceae | Stem wood, bark, and leaf | Essential oil, phenolic acids, and flavonoids | Regulates oxidative stress and hypertension | [ |
|
| Fabaceae | Leaf | Polyphenolic compounds | Regulates oxidative stress and inflammation | [ |
|
| Asteraceae | Aerial part | Flavonoids and phenolic compounds | Attributes to lipid-lowering action and the inhibition of free radical generation | [ |
|
| Berberidaceae | Stem, bark, root, and bark | Berberine | Regulates metabolism, immunity, and oxidative reactions | [ |
|
| Theaceae | Leaf | Terpenoid and saponins | Induces cardioprotection against ischemia-reperfusion injury through activation of the bradykinin-NO pathway followed by the suppression of reactive oxygen species | [ |
|
| Theaceae | Leaf | Catechins, sterols, alkaloids, and terpenoids | Reduces the level of total cholesterol, low-density lipoprotein cholesterol, nonhigh-density lipoprotein cholesterol, and apolipoprotein B | [ |
|
| Asteraceae | Flower | Chalcone compounds | Lower blood pressure and reduce rennin activity | [ |
|
| Rutaceae | Fruit | Flavonoids | Manages cardiotoxicity due to its antioxidative and lipid-lowering effects | [ |
|
| Arecaceae | Stem, leaf, seeds, and flower | Phenols, tannins, leucoanthocyanidins, flavonoids, triterpenes, steroids, and alkaloids | Minimizes oxidative stress and cell harm | [ |
|
| Apiaceae | Seeds | Essential oils and polyphenols | Controlls diabetic dyslipidemia to prevent cardiovascular complications | [ |
|
| Iridaceae | Flower stigma | Essential oil, crocin, crocetin, and picrocrocin | Shows beneficial results against hypertension and atherosclerosis | [ |
|
| Moraceae | Leaf | Essential oil | Decreases systolic blood pressure in hypertension | [ |
|
| Zingiberaceae | Rhizome | Curcumin | cardioprotective effects through reducing oxidative stress | [ |
|
| Labiatae | Seeds | Flavonoids: Tilianin, luteolin, and rosmarinic acid | Reduces the IL-1 | [ |
|
| Cyperaceae | Fruit | Amino acids, carbohydrates, phenolics, sterols, and saponins | Plays an essential role in cardiovascular homeostasis | [ |
|
| Clusiaceae | Fruit | Phenolic compounds and flavonoids | Cardioprotective against myocardial injury | [ |
|
| Ginkgoaceae | Leaf | Flavonoids and terpenoids | Promotes cardiomyocyte survival and inhibits cardiomyocyte apoptosis through the modulation of the PI3K-AKT and NF- | [ |
|
| Angiospermae | Seeds | Isoflavones: genistein, daidzein, and glycitin in glycoside forms | Improves vascular reactivity, increases low-density lipoprotein oxidation resistance, and inhibits thrombus formation | [ |
|
| Cucurbitaceae | Aerial part | Saponins | Shows inhibition towards oxidized low-density lipoprotein induced foam cell formation and accumulation of intracellular lipids, controls cholesterol metabolism, displays synergistic activities in lowering lipid synthesis, and increases oxidation. | [ |
|
| Moringaceae | Leaf | Saponins | Reduces the cholesterol in blood and blood pressure | [ |
|
| Moringaceae | Leaf | Alkaloids, saponins, polyphenols, terpenoids, and cardiac glycosides | Treats high blood pressure | [ |
|
| Ranunculaceae | Seeds | Cinnamaldehyde | Decreases oxidative stress and regulates avert hypertension development | [ |
|
| Lamiaceae | Leaf | Eugenol | Displays the significant treatment of cardiovascular effects via blood pressure lowering | [ |
|
| Oleaceae | Leaf | Iridoids and secoiridoids | Exhibits cardioprotective role against lipid oxidation and cholesterol efflux | [ |
|
| Araliaceae | Berry, leaf, root | Protopanaxadiol, protopanaxatriol, and oleanane | Regulates blood pressure and circulation | [ |
|
| Lauraceae | Seeds | Flavonoids and polyphenols | Attenuates doxorubicin-induced cardiotoxicity | [ |
|
| Arecaceae | Fruit | Flavonoids and phenolic compounds | Shows a cardio- protective effect on the heart tissue against cardiotoxicity induced by doxorubicin treatment | [ |
|
| Rosaceae | Root | Triterpenoids | Up/downregulation of many signalling pathways regarding their cardiovascular properties | [ |
|
| Crassulaceae | Root | Monoterpene alcohols and their glycosides, cyanogenic glycosides, and flavonoids | Cardiovascular diseases prevention | [ |
|
| Rosaceae | Flowers | Flavonoids, glycosides, and anthocyanins | Cardiovascular disease prevention through regulating oxidative stress and blood lipids | [ |
|
| Polygonaceae | Root, stem, leaf | Anthracene derivatives, flavonoids, and procyanidins | Reduces the risk of developing of cardiovascular activities through controlling blood lipid accumulation, obesity, and oxidative stress | [ |
|
| Fabaceae | Seeds | Isoflavones: daidzein, genistein, formononetin, and biochanin A | Prevents cardiovascular diseases via controlling the cholesterol level | [ |
|
| Lamiaceae | Rhizome | Salvianolic acids | Modulates endothelial hemostasis by increasing plasminogen activator, anticoagulant thrombomodulin, eNOS dependent NO production, inhibits LDL oxidation, and extravasation, ensures OxLDL-induced endothelial cell injury | [ |
|
| Solanaceae | Fruit | Flavonoids | Reduces the risk of human cardiovascular diseases through lowering blood pressure and monitors type 2 diabetes | [ |
|
| Fabaceae | Root | Rutin | Traditional therapy for the cardioprotective action | [ |
|
| Ericaceae | Fruit | Anthocyanins | Decreases LDL-C/TG and increases HDL-C levels | [ |
|
| Melanthiaceae | Root | Resveratrol | Cardiovascular protection against inflammation and oxidative stress | [ |
|
| Caprifoliaceae | Aerial part | Anthocyanins | Cardiovascular protection through regulating blood lipids, obesity, and oxidative stress | [ |
|
| Zingiberaceae | Rhizome | 6-Shogaol, 6-gingerol, 8-gingerol, and 10-gingerol | Enhances fibrinolytic activity and decreases lipid peroxidation, controls blood glucose levels and blood pressure, lipid concentration, and reduces the pain claimed by rheumatoid arthritis affected patients | [ |
Mechanism of action of some medicinal plants for cardiovascular disease treatments.
| Plant | Phytoconstituents | Mechanism of action | Reference |
|---|---|---|---|
|
| Polyphenols, amino acids, theanine, proanthocyanins, caffeine, catechin, epicatechin, gallocatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, and gallocatechin gallate | It prevents human vascular endothelial cells from oxidative stress. | [ |
| (i) Through activating autophagy through the mTOR pathway by delaying apoptosis upon endoplasmic reticulum stress | |||
| (ii) Increases the expression levels of proteins | |||
| Relates to autophagy and connexin in neonatal cardiomyocytes with high glucose by restoring AMPK activity | |||
| (iii) Inhibitions of autophagy | |||
| By preserving connexin expression in cells stimulated by high glucose levels | |||
|
| |||
|
| Fat-soluble aromatic phytoextract that obtained from ginger plant rhizome and curcumin | Controls hypertensive effects | [ |
| (i) By lowering blood pressure, it can increase myocardial trophic blood flow. | |||
| (ii) By reducing the viscosity of blood and thrombosis formation through hindering the synthesis of thromboxane A2 (TXA2) | |||
| Prevents platelet activation and aggregation | |||
| (i) By regulating calcium signals | |||
| Inhibiting the activation of NF- | |||
| (i) By protecting and activating vascular endothelial cells from incapacitation, which reduces arterial sclerosis, thrombosis, and abnormal blood pressure | |||
|
| |||
|
| Steroid glycosides and digoxin | Protects cardiomyocytes | [ |
| (i) By opening of the KATP channel, increase secretion of atrial natriuretic peptide, cardiac hypertrophy, oxidative stress, and apoptosis | |||
| Protective in macrophages and monocytes | |||
| (i) By estrogen receptor activation, NOS-NO signalling pathway inhibition, and nuclear receptor peroxisome proliferator-activated receptor | |||
| Exerts protective therapeutic effects | |||
| (i) By inhibiting, modulating, and regulating the expression of contractile and structural proteins and glycoproteins | |||
| (ii) By regulating the calcium levels and improving the functioning of mitochondria | |||
|
| |||
|
| Gentiopicroside, swertiamarin, sweroside, isogentisin, bellidifolin, mangiferin, isoorientin, isovitexin, | Prevents platelet activation | [ |
| (i) By inhibiting phosphorylation of phospholipase C(PLC)2-PKC cascade and the MAPK pathway so that amarogentin may offer therapeutic potential for treating thromboembolic disorders | |||
| Blood pressure lowering | |||
| (i) Through inhibition of Ca2+ ingress and release from intracellular stores | |||
| Prevents and treats atherosclerosis | |||
| (i) Through inhibition of vascular smooth muscle cell proliferation | |||
| Exhibits anticoagulant activity | |||
| (i) An endothelium-independent vasodilator activity in aortic rings precontracted by norepinephrine a marked depression of the contracturant response by KCl, caffeine, and norepinephrine | |||
|
| |||
|
| Phenolic compounds, saponins, triterpenes, branched glycosylated, oleanane saponins, furostane saponin, rutin, kaempferol, and iridoid ebuloside | Lowering blood pressure | [ |
| (i) By inhibiting cardiac contraction | |||
| (ii) By regulating rate of heart beat | |||
| (iii) By improving cardiac output with the ultimate decrease in arterial blood pressure | |||
| (iv) Control raised mean arterial pressure and heart rate | |||
| (v) By blocking calcium ion channel | |||
|
| |||
|
| Dammarane-type saponins and gypenosides | Protection of embryonic cardiomyocytes H9c2 from I/R injuries | [ |
| (i) By downregulating the production of intracellular ROS and recovering mitochondrial membrane potential to normal levels | |||
| (ii) By the activation of the PI3K/Akt pathway | |||
| Reduction of cell apoptosis from I/R stimulus | |||
| (i) By decreasing the expression of apoptotic proteins such as bax and caspase-3/-9 | |||
| (ii) Blocking of the homologous protein pathway | |||
| (iii) By inhibiting the apoptosis caused by endoplasmic reticulum stress | |||
|
| |||
|
| Flavonoids, glucomoringin, | Targets angiotensin-converting enzyme (ACE) | [ |
| (i) Through antihypertensive activity | |||
| (ii) Treats obesity and its cardioprotective effects | |||
| (iii) Regulates the cardiac induced by a high-fat diet feeding | |||
| (iv) Manages obesity and its related heart complications | |||
|
| |||
|
| Alkaloids, flavonoids, and thymoquinone | Prevents cell injuries | [ |
| (i) By reducing the free radical formation | |||
| (ii) By scavenging free radical species from blood | |||
|
| |||
|
| Flavones and oncoglabrinol C | Protection of endothelial cells | [ |
| (i) By controlling oxidative stress and apoptosis | |||
| (ii) By modulating hepatic CYP3A4 activity | |||
|
| |||
|
| Flavonoids, flavonolignans, quercetin, taxifolin, eriodyctiol, silibinin, and chrysoeriol | Controls inflammation | [ |
| (i) Activates the Nrf2/HO-1 signalling pathway | |||
| (ii) Inhibits the NF-Κb/NLRP3 signalling pathway | |||
| Reduces cardiomyocytes | |||
| (i) By reducing doxorubicin and ameliorated inflammation and oxidative stress by activating PPAR- | |||
| (ii) By regulating antioxidant activity in oxidative stress-induced cardiovascular diseases | |||
| Treatment of type 2 diabetes mellitus | |||
| (i) Improving the glycemic index and lipid profile significantly | |||